



## Interagency Coordinating Committee on the Validation of Alternative Methods

# Collaborative Modeling Project for Acute Inhalation Toxicity (CoMPAIT)

NICEATM

Agency for Toxic Substances and Disease Registry • Consumer Product Safety Commission • Department of Agriculture  
Department of Defense • Department of Energy • Department of the Interior • Department of Transportation  
Environmental Protection Agency • Food and Drug Administration • National Institute for Occupational Safety and Health  
National Institute of Standards and Technology • National Institutes of Health • National Cancer Institute • National Library of Medicine  
National Institute of Environmental Health Sciences • Occupational Safety and Health Administration

# Outline

## Background

ICCVAM & AcuteTox

Agency requirements for inhalation data

## The dataset

Collection

Curation

Analysis (variability)

## Modeling strategy

Endpoint & challenges

Training and validation

Consensus

# Acute Toxicity Testing

## Complete – oral and dermal systemic toxicity

Evaluate the usefulness of acute oral LD50 data for classifying dermal systemic hazard of potential toxicants such as pesticides, industrial chemicals, chemical warfare agents, and household chemicals

Complete – for pesticide formulations and active ingredients; EPA published waiver guidance for formulations in 2016 and for technical chemicals in 2020

## Evaluate in vitro/in silico approaches for predicting acute systemic toxicity

Modeling workshop convened – workshop report published (Kleinstreuer et al. 2018; <https://doi.org/10.1016/j.comtox.2018.08.002>)

Acute oral toxicity in silico models – CATMoS (Mansouri et al. 2021; <https://doi.org/10.1289/EHP8495>); model predictions for ICCVAM agencies

Variability analysis of the in vivo oral test method (manuscript published – Karmaus et al. 2022; <https://doi.org/10.1093/toxsci/kfac042>)

## GHS additivity formula evaluation for acute systemic toxicity tests

Manuscript published – Hamm et al. 2021; <https://doi.org/10.1016/j.yrtph.2021.105007>

## Publish a scoping document that outlines the current requirements and testing needs for U.S. and international regulatory authorities

U.S. published (Strickland et al. 2018; <https://doi.org/10.1016/j.yrtph.2018.01.022>)

International published (Strickland et al., 2023; <https://doi.org/10.1080/10408444.2023.2240852>)



SOT | Society of Toxicology  
academic.oup.com/toxsci

TOXICOLOGICAL SCIENCES, 188(1), 2022, 34–47

<https://doi.org/10.1093/toxsci/kfac042>  
Advance Access Publication Date: 15 April 2022  
Research article

## Evaluation of Variability Across Rat Acute Oral Systemic Toxicity Studies

Regulatory Toxicology and Pharmacology 125 (2021) 105007



Contents lists available at ScienceDirect

Regulatory Toxicology and Pharmacology

journal homepage: [www.elsevier.com/locate/yrtph](http://www.elsevier.com/locate/yrtph)



## Performance of the GHS Mixtures Equation for Predicting Acute Oral Toxicity

Jon Hamm<sup>a,\*</sup>, David A. Jenny Tao<sup>b</sup>, Nicole Kle



Regulatory Toxicology and Pharmacology

Volume 94, April 2018, Pages 183–196



<sup>a</sup> ILS, P.O. Box 13501, Research Triangle Park, NC, 27709  
<sup>b</sup> Office of Pesticide Programs, U.S. Environmental Protection Agency, 12233, Research Triangle Park, NC, 27709

## Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies

Judy Strickland<sup>a</sup>, Amy J. Clippinger<sup>b</sup>, Jeffrey Brown<sup>b</sup>, David Allen<sup>a</sup>, Abigail Jacobs<sup>c,1</sup>, Joanna Matheson<sup>d</sup>, Anna Lowit<sup>e</sup>, Emily N. Reinke<sup>f</sup>, Mark S. Johnson<sup>f</sup>, Michael J. Quinn Jr.<sup>f</sup>, David Mattie<sup>g</sup>, Suzanne C. Fitzpatrick<sup>h</sup>, Surender Ahir<sup>i</sup>, Nicole Kleinstreuer<sup>j</sup>, Warren Casey<sup>j</sup>

# ICCVAM Agencies requirements

## Multiple U.S. Federal and International agencies require inhalation data

- Determine occupational exposure safety limits
- Requirements for protective gear
- Consumer safety levels
- Packaging and transportation requirements and limits


- **Alternative Approaches for Acute Inhalation Toxicology Testing Workshop in September 2016 identified the need for 4 working groups, one of which should:**

- Establish a database of acute inhalation toxicity tests
  - Required to build and evaluate alternative models
  - Data collection, curation, and cleanup occurred from 2018 – 2022





# Global Crowdsourcing Predictive Models



- International consortium : academia, industry, govt
- Curate reference data to train & test models:
- Use molecular structure and chemical properties to predict toxicity (e.g. endocrine disruption, acute systemic effects)
- Combine best models together into “ensemble” approaches
- Create open access AI/ML modeling suite



<https://github.com/NIEHS/OPERA>

## CERAPP

Collaborative Estrogen Receptor  
Activity Prediction Project (2015/16)

Mansouri et al. (<https://doi.org/10.1289/ehp.1510267>)

## CoMPARA

Collaborative Modeling Project for  
Androgen Receptor Activity (2017/18)

Mansouri et al. (<https://doi.org/10.1289/EHP5580>)

## CATMoS

Collaborative Acute Toxicity Modeling  
Suite (2019/20)

Kleinstreuer et al. (<https://doi.org/10.1016/j.comtox.2018.08.002>)

Mansouri et al. (<https://doi.org/10.1289/EHP8495>)



Endocrine Disruptor Screening Program



Acute Toxicity Workgroup: alternative methods

ICCVAM: Interagency Coordinating Committee on the Validation of Alternative Methods

# Outline (2)

## Background

ICCVAM & AcuteTox

Agency requirements for inhalation data

## The dataset

Collection

Curation

Analysis (variability)

## Modeling strategy

Endpoint & challenges

Training and validation


Consensus

# Inventory Sources and Data Collected

- **ChemIDplus**
  - Data Rows: 2036
  - Unique Substances: 1249
- **NIOSH Pocket Guide**
  - Data Rows: 136
  - Unique Substances: 649
- **ECHA REACH Database**
  - Data Rows: 3016
  - Unique Substances: 611
- **EPA AEGL**
  - Data Rows: 1682
  - Unique Substances: 271
- **Department of Defense**
  - Data Rows: 47
  - Unique Substances: 13
- **Data Types Collected**
  - Chemical ID information
    - Name, CASRN, DTXSID, SMILES, Inchikey
  - Chemical type information and source
  - Species/Strain/Sex
  - Route/Phase of Exposure (aerosol, gas, vapor)
  - Exposure type (nose only or whole body)
  - Vehicle
  - Duration
  - Concentration (mg/L, ppm, mg/m<sup>3</sup>)
  - Additional clarifying data



# Data curation



## Data Quality Flags (examples)

Missing or incorrect units

Missing study duration

Species other than rat

Incorrect route of administration

Study type indicated as read across

## Deduplication Requirements

Difference in LC50 values  $\leq 0.1$  mg/L

Duration is equal or unreported

Sex is the same or unreported

Route of administration matches

\*GHS, EPA OPP, EPA OPPT, CPSC, etc.

# Data distribution

2109 entries, 1025 chemicals

98 chemicals overlap


343 chemicals (14 overlap)

76%


Mean = 35.75 mg/L , SD = 253 mg/L

20%


4%



LC50 entries: 1635; chemicals: 780




Limit test entries: 420; Chemicals: 312  
(lower: 301 ; upper: 15)



Range entries: 54 ; chemicals: 45

# Functional use categories



- To determine potential associations between functional use and LC50 variability, data were obtained from EPA's Chemicals and Products Database (CPDat v4.0.0.alpha) accessed through ChemExpo (<https://comptox.epa.gov/chemexpo/>).
  - CPDat contains reported functional uses harmonized to 107 functional use categories defined by the Organisation for Economic Co-operation and Development (OECD).
- Of the 231 chemicals with at least two LC50 point estimates, 142 had an OECD functional use in CPDat.
  - These chemicals span 61 of the 107 functional use categories in CPDat.
  - Chemicals had as many as 20 functional uses (n=20 for 2-butoxyethanol)

*Median absolute deviation of 4-hour LC50s for functional use categories with at least five unique chemicals.*

# Outline (3)

## Background

ICCVAM & AcuteTox

Agency requirements for inhalation data

## The dataset

Collection

Curation

Analysis (variability)

## Modeling strategy

Endpoint & challenges

Training and validation

Consensus

## Endpoints of interest

- Continuous: LC50 (mg/L), 4-hour exposure
- Categorical: hazard category schema
  - GHS
  - EPA OPPT
  - EPA OPP
  - CPSC
  - DoT



## GHS Categories

GHS Category	Gases (ppm)	Vapors (mg/L)	Dust and Mists (mg/L)
1	$LC50 \leq 100$	$LC50 \leq 0.5$	$LC50 \leq 0.05$
2	$100 < LC50 \leq 500$	$0.5 < LC50 \leq 2.0$	$0.05 < LC50 \leq 0.5$
3	$500 < LC50 \leq 2500$	$2.0 < LC50 \leq 10.0$	$0.5 < LC50 \leq 1.0$
4	$2500 < LC50 \leq 20,000$	$10.0 < LC50 \leq 20.0$	$1.0 < LC50 \leq 5.0$
Not classified	$LC50 > 20,000$	$LC50 > 20.0$	$LC50 > 5.0$

## EPA OPPT Categories

Hazard Ranking	Gas/Vapor (mg/L)	Dust and Mists (mg/L)
3 (high)	$<2.0 < LC50 \leq 10$	$<0.5 < LC50 \leq 1.0$
2 (moderate)	$10.0 < LC50 \leq 20.0$	$1.0 < LC50 \leq 5.0$
1 (low)	$LC50 > 20.0$	$LC50 > 5.0$

## EPA OPP Categories

EPA Category	Criteria	Entries	Chemicals
I	$LC50 \leq 0.05$	212	86
II	$0.05 \text{ mg/L} < LC50 \leq 0.5$	425	212
III	$0.5 \text{ mg/L} < LC50 \leq 2.0$	273	165
IV	$LC50 > 2.0$	1165	641

## CPSC Categories

Category	Gas or Vapor (ppm)	Dusts/mists (mg/L)
Highly toxic	$LC50 \leq 200$	$LC50 \leq 2$
Toxic	$200 < LC50 \leq 20,000$	$2 < LC50 \leq 200$
Nontoxic	$LC50 > 20,000$	$LC50 > 200$

## Endpoints of interest (2)

- Continuous: LC50 (mg/L), 4-hour exposure
- Categorical: hazard category schema

5 categories	– GHS: 3 phases (gas, vapor, aerosol)
3 categories	– EPA OPPT: 2 phases (gas, aerosol)
4 categories	– EPA OPP: No phases
3 categories	– CPSC: 2 phases (gas, aerosol)
5 categories	– DoT: 2 phases (gas, aerosol)



Total 11 endpoints if modeled separately!

# Determining Exposure Phase

- The phase of exposure is necessary for mapping to many of the toxicity endpoints (cutoffs are determined by phase)
- We consider 3 phases for inhalation:
  1. **Gas**
  2. **Vapor**
  3. **Aerosol** (includes **Dust and Mist**)
- Limited data had phase reported (28%)
  - We harmonized reported phase to **gas**, **vapor**, and **aerosol**
  - Some studies report both **vapor** and **aerosol** for a chemical

# Predict Phase of Exposure Using OPERA

Melting point (MP), boiling point (BP), and vapor pressure (VP)

Physical State Rules	Physical State	Atmospheric State Rules	Atmospheric State	Exposure Phase Justification	Exposure Phase
MP $\leq$ 25°C	liquid	VP $\leq$ 10 <sup>-8</sup> mmHG	particulate	atmospheric state is particulate	aerosol
MP > 25°C	solid	VP $\leq$ 10 <sup>-8</sup> mmHG	particulate	atmospheric state is particulate	aerosol
MP $\leq$ 25°C	liquid	10 <sup>-8</sup> mmHG < VP < 10 <sup>-4</sup> mmHG	vapor and particulate	atmospheric state is vapor and particulate	aerosol;vapor
MP > 25°C	solid	10 <sup>-8</sup> mmHG < VP < 10 <sup>-4</sup> mmHG	vapor and particulate	atmospheric state is vapor and particulate	aerosol;vapor
BP $\leq$ 25°C	gas	VP $\geq$ 10 <sup>-4</sup> mmHG	vapor	physical state is gas	gas
MP $\leq$ 25°C	liquid	VP $\geq$ 10 <sup>-4</sup> mmHG	vapor	atmospheric state is vapor and physical state is liquid	aerosol;vapor
MP > 25°C	solid	VP $\geq$ 10 <sup>-4</sup> mmHG	vapor	atmospheric state is vapor and physical state is solid	aerosol;vapor

Limited data had phase reported (28%)

715 rows out of ~2500 have an extracted phase


Phase	# Rows Reported	# Correctly Predicted
Gas	43	30 (69.7%)
Vapor	374	369 (98.7%)
Aerosol	303	302 (99.7%)

# Proposed endpoint to be modeled

LC50 point estimate in **mg/L** and **ppm** (After modeling, select 1 or consensus of both)

- Training and test sets:**

765 chemicals (with QSAR-ready structures)



- 80% training set: 612 chemicals
- 20% evaluation set: 153 chemicals

- Prediction set:**

48137 QSAR-ready structures to be predicted (CATMoS list).

Included Lists:

- ToxCast/Tox21
- EDSP
- TSCA
- Substances on the market (EPA)



# Proposed modeling strategy

## 1. Modeling step:

- Endpoints to be modeled:
- LC50 values (2 units)

## 2. Consensus model:

- Combine the single models into consensus
- Apply WoE for consistency

## 3. Physical forms:

- Physicochemical properties to assign physical states
- Convert specific predictions (units)

## 4. Regulatory systems:

- Apply the corresponding thresholds for the different regulatory classification systems

# Evaluation Criteria

The five OECD principles for QSAR validation to be considered as guidance:

**1. A defined endpoint**

- Separate models should be submitted corresponding to the five endpoints defined above.

**2. An unambiguous algorithm**

- Ensure transparency in the description of the model algorithm. Preference will be given to models using simple algorithms and open-source code.

**3. A defined domain of applicability**

- Define limitations in terms of the types of chemical structures, physicochemical properties and mechanisms of action for which the models can generate reliable predictions. Including ability to characterize uncertainty/confidence is a plus.

**4. Appropriate measures of goodness-of-fit, robustness and predictivity**

- Quantitative performance, including cross-validated training set performance and external test set performance (will be recalculated by the project organizers).

**5. Mechanistic interpretation, if possible**

- Mechanistic associations between the descriptors used in a model and the endpoint (mode of action) being predicted.

## Timeline

- July 1st: Access to training and prediction sets (Box folder)
- Oct 1: Modeling results, predictions, and summary/description
- Oct 15: Access granted to test/evaluation set identifiers
- Nov 30: Organizing committee evaluation results, detailed documentation
- Dec 30: Corrections and additional documentation to models
- Jan 30: Consensus model and evaluation
- Mar 30: Drafting manuscript
- June 30: Submit manuscript


# Participating groups



*SimulationsPlus*



Johns Hopkins  
Center for Alternatives  
to Animal Testing



**UFG**  
UNIVERSIDADE  
FEDERAL DE GOIÁS



ISTITUTO DI RICERCHE  
FARMACOLOGICHE  
MARIO NEGRI - IRCCS

**Insilica.co**



National Center  
for Advancing  
Translational Sciences



UNIVERSITÀ  
DEGLI STUDI DI BARI  
ALDO MORO

DIPARTIMENTO DI  
FARMACIA -  
SCIENZE DEL FARMACO



**UCLA**



THE UNIVERSITY  
of NORTH CAROLINA  
at CHAPEL HILL



**HELMHOLTZ MUNICH**

Pacific Northwest  
NATIONAL LABORATORY



## The NICEATM Group (2024)



**ICCVAM (ATWG & EcoWG)  
EPA EFED  
All international collaborators**



**Subscribe to NICEATM News email list**  
<https://ntp.niehs.nih.gov/go/niceatm>



# Thank you for your attention!



Question

OR



Comment

**Acknowledgments:**



**NICEATM**

**inotiv**  
analyze. answer. advance.